Arcus Biosciences Inc (RCUS)
Current ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 1,016,000 | 831,000 | 1,067,000 | 1,262,000 | 735,815 |
| Total current liabilities | US$ in thousands | 226,000 | 184,000 | 193,000 | 166,000 | 121,669 |
| Current ratio | 4.50 | 4.52 | 5.53 | 7.60 | 6.05 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,016,000K ÷ $226,000K
= 4.50
The current ratio of Arcus Biosciences Inc has demonstrated a generally positive trend over the years, indicating a healthy liquidity position. As of December 31, 2020, the current ratio stood at 6.05, signifying a strong ability to meet short-term obligations with current assets. This ratio further improved to 7.60 by December 31, 2021, reflecting a strengthening liquidity position.
However, there was a slight decline in the current ratio to 5.53 by December 31, 2022, followed by a more notable decrease to 4.52 by December 31, 2023. This reduction indicates a potential decrease in the company's ability to cover its short-term liabilities with current assets.
As of the most recent date available, December 31, 2024, the current ratio remained relatively stable at 4.50. While the ratio is still above 1, suggesting that Arcus Biosciences Inc can meet its short-term obligations, there may be a need for ongoing monitoring to ensure liquidity remains adequate.
Peer comparison
Dec 31, 2024